EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 4.0

Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities

Linda Stein Gold, Howard L Sofen, Kimberly Siu, Sakil Syeed, Emily Edson-Heredia, Beth Mitchell, Emily Goddard, Bruno Kranz, Liane Gillespie-Akar, April W Armstrong

Dermatology and Therapy · 29.10.2026

DOI: 10.1007/s13555-026-01899-4 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Dermatology and Therapy, online erschienen am 29.10.2026. Verfasst von Linda Stein Gold und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Henry Ford Health, Detroit, MI, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Psoriasis (PsO) is a chronic inflammatory skin disorder with variable severity. Traditional trial criteria based on Psoriasis Area and Severity Index (PASI) and body surface area (BSA) may not adequately reflect disease burden, particularly in patients with high-impact site involvement (scalp, groin/genitals, hands/feet, armpits). This study aimed to describe treatment outcomes, clinical characteristics, and satisfaction among patients receiving biologics or advanced oral therapies in real-world practice.

Methods

This cross-sectional analysis used data from the 2024 Psoriasis Wave XI of the Adelphi Real World Disease Specific Programme™ in the USA. Dermatologists completed patient record forms, and patients completed linked patient self-completion questionnaires. Patients were stratified by current treatment (biologics/biosimilars vs. advanced oral therapies) and physician-assessed disease severity (mild vs. moderate-to-severe). Descriptive and bivariate analyses were conducted.

Results

Among 682 patients, 466 (68.3%) had mild PsO and 216 (31.7%) had moderate-to-severe PsO. Of 517 receiving advanced systemic therapies, 134 (25.9%) received advanced oral therapies and 383 (74.1%) biologics. Prior to treatment initiation, mean BSA was similar between treatment groups (13.4% vs. 14.7%; p = 0.408), whereas PASI was lower in the advanced oral therapies group (6.2 vs. 9.3; p < 0.001). At consultation, BSA and PASI remained higher in the moderate-to-severe versus mild group (BSA 10.7% vs. 3.0%; PASI 7.9 vs. 2.0; both p < 0.001). Physician-reported satisfaction was lower for advanced oral therapies than biologics (50.0% vs. 75.0%), with moderate physician–patient agreement in both groups (kappa = 0.434 and 0.593, respectively).

Conclusion

In this real-world study, mean PASI scores before treatment initiation were below typical clinical trial thresholds, highlighting a disconnect between trial eligibility criteria and clinical practice. Low physician-reported satisfaction with advanced oral therapies suggests ongoing unmet need for some patients receiving advanced oral therapy. These findings support broader, more patient-centered eligibility criteria that better reflect real-world PsO burden and treatment needs.

Schlagwörter

Stichwörter der Autor:innen

Advanced oral therapiesBiologicsPsoriasisReal-world evidenceTreatment outcomesTreatment satisfaction

Autor:innen und Institutionen

  • Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
  • University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.
  • Dermatology Research Associates, Los Angeles, CA, USA.
  • Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN, 46285, USA.
  • Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN, 46285, USA. mitchell_beth_d@lilly.com.
  • Adelphi Real World, Bollington, UK.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Stein Gold, L., Sofen, H. L., Siu, K., Syeed, S., Edson-Heredia, E., Mitchell, B., Goddard, E., Kranz, B., Gillespie-Akar, L., & Armstrong, A. W. (2026). Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01899-4

Vancouver

Stein Gold L, Sofen HL, Siu K, Syeed S, Edson-Heredia E, Mitchell B, et al. Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities. Dermatology and Therapy. 2026. doi:10.1007/s13555-026-01899-4

BibTeX
@article{SteinGold2026,
  author = {Stein Gold, Linda and Sofen, Howard L and Siu, Kimberly and Syeed, Sakil and Edson-Heredia, Emily and Mitchell, Beth and Goddard, Emily and Kranz, Bruno and Gillespie-Akar, Liane and Armstrong, April W},
  title = {Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities},
  journal = {Dermatology and Therapy},
  year = {2026},
  doi = {10.1007/s13555-026-01899-4}
}
Kostenlos starten →